RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 41 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 41

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  2. Study siteChongqing General Hospital重庆大学附属中心医院(重庆市人民医院)ChongqingHospital page
  3. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  4. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  5. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  6. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  7. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  8. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  9. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  10. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  11. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  12. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  13. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  14. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  15. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  16. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  17. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  18. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  19. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  20. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  21. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  22. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  23. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  24. Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
  25. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  26. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  27. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  28. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  29. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  30. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  31. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  32. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  33. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  34. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  35. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  36. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  37. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  38. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  39. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  40. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page
  41. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06361888, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pancreatic cancer confirmed by histology or cytology;

    Inclusion criterion 3

  3. Received major surgical surgery within 4 weeks before the first dose;

    Exclusion criterion 3

    Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;

    Exclusion criterion 4

    Received strong-inducers or strong-inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose;

    Exclusion criterion 6

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;

    Inclusion criterion 7

  5. According to RECIST 1.1, there is at least one measurable lesion;

    Inclusion criterion 6

  6. Presence of other malignancies in the past 5 years;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06361888, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process;
  • Age range is 18-75 years old (inclusive);
  • Pancreatic cancer confirmed by histology or cytology;
  • Stage IV metastasis Pancreatic cancer patients;
  • Have not received previous systematic first line anti-tumor treatment in the stage of metastatic pancreatic cancer;
  • According to RECIST 1.1, there is at least one measurable lesion;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;
  • Expected survival time ≥ 12 weeks;

Exclusion Criteria:

  • Use of systematic non-specific immunomodulatory therapy within 2weeks prior to the first dose;
  • Presence of other malignancies in the past 5 years;
  • Received major surgical surgery within 4 weeks before the first dose;
  • Received palliative radiotherapy within 1 week before the first dose; received radical radiotherapy within 4 weeks before the first dose;
  • Any known allergy to surufatinib or its components, camrelizumab, nab-paclitaxel, or gemcitabine;
  • Received strong-inducers or strong-inhibitors of cytochrome P450 (CYP) 3A within 2 weeks or 5 half-lives (whichever is longer) before the first dose;
  • Use of immunosuppressive drugs within 4 weeks before first dose;
  • Known history of clinically significant liver disease, including active viral hepatitis infection or other active hepatitis or clinically significant moderate to severe cirrhosis;
  • Patients who currently have hypertension that cannot be controlled by medication;

Quoted from ClinicalTrials.gov, NCT06361888, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06361888, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06361888